# VISEN Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/visen-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.visenpharma.com/
- Total disclosed funding: $150M
- Latest round: Series B (Jan 4, 2021)
- Investors on record: 11

## About

Founded in 2018 and based in Suzhou, China, VISEN Pharmaceuticals is a new drug developer that focuses on endocrine-related therapeutic areas. It has offices in Shanghai, Beijing, Hong Kong, and Taipei. The CEO of the company, Anbang Lu graduated from the Department of Pharmacy, Taipei Medical University. The Company's lead drug, lonapegsomatropin, was IND-approved for a Phase 3 clinical trial in China starting in October 2019, and reached the trial's primary endpoint in May 2022. In March 2025, VISEN Pharmaceuticals raised USD 72 million in Pre-IPO funding from new investors Anhui Anke Biotechnology (Group) Co., Ltd., Harvest Capital, WuXi Biologics (Cayman) Inc., and Reynold Lemkins, and returning investor Vivo Capital, and was listed on the Hong Kong Stock Exchange and Clearing Limited. The company focuses on innovative biopharmaceutical research and development in the field of endocrine-related therapeutics. The product pipeline includes lonapegsomatropin and navepegritide in the field of pediatric endocrinology, and palopegeriparatide in the field of adult endocrinology. Lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years. Navepegritide is used to treat achondroplasia in children aged 2 to 10 years. Palopegteriparatide is used to treat chronic hypoparathyroidism. The company generates revenue by providing innovative biopharmaceuticals in the field of endocrine-related treatment. The company will use the IPO funding for the research and development of core products and BLA registration, expansion of clinical trials for new indications, commercialization and expansion research of products lonapegsomatropin, palopegteriparatide, and navepegritide, and allocation of working capital and other general corporate purposes.

## Funding rounds

- Series B, Jan 4, 2021, $150M — OrbiMed Advisors, Hong Shan, Sofinnova Investments, HBM Partners, Vivo Capital, Ascendis Pharma A/S, Cormorant Asset Management, Pivotal Life Sciences, Sherpa Healthcare Partners, Logos Capital, CDG Capital
- Series A, Feb 15, 2019 — Sofinnova Investments, Vivo Capital, Ascendis Pharma A/S

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- Ascendis Pharma A/S — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Hong Shan — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- CDG Capital (https://capitalatlas.ai/funds/cdg-capital) — Series B